# Triple-negative breast cancer research developments

> Live situation record from CLSTR: https://clstr.news/situations/triple-negative-breast-cancer-research-developments
> Updated: 2026-08-31T17:57:00.000Z. Sources: 4. Developments: 2.

Recent research has identified new mechanisms and therapeutic strategies to combat triple-negative breast cancer (TNBC).

Researchers at the National University of Singapore identified a regulatory mechanism called the ‘DP103 master switch’ that drives tumor growth and resistance. Using the drug RX-5902 (Supinoxin) in laboratory models, they were able to deactivate processes within the Wnt signaling pathway, resulting in a 40 to 60 percent reduction in cancer stem cell viability.

In a separate study, researchers at the Medical University of South Carolina developed a ‘one-two-punch’ dual-drug strategy. This method targets the protein lysyl oxidase (LOX) to weaken cancer cells, subsequently using a second drug to block backup survival pathways. In preclinical models, this approach significantly inhibited tumor growth without relying on chemotherapy.

## Timeline

### 2026-08-31: MUSC researchers develop dual-drug strategy for triple-negative breast cancer

MUSC Hollings Cancer Center researchers have developed a dual-drug strategy to target triple-negative breast cancer by blocking the LOX protein to create vulnerabilities in chemoresistant cells.

2 sources. https://clstr.news/cluster/musc-researchers-develop-dual-drug-strategy-for-triple-negative-breast-cancer

### 2026-08-23: National University of Singapore researchers identify breast cancer target

National University of Singapore researchers identified the DP103 master switch in triple-negative breast cancer and a drug, RX-5902, that can significantly reduce tumor growth and cell viability.

2 sources. https://clstr.news/cluster/national-university-of-singapore-researchers-identify-breast-cancer-target

---
Cite as: Triple-negative breast cancer research developments. CLSTR, https://clstr.news/situations/triple-negative-breast-cancer-research-developments